Heart failure & cardiomyopathiesRandomised controlled trial
Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics
- Randomised controlled trial
- multicentre
- open-label
- active-comparator
Authors' conclusion
In patients with heart failure and loop diuretic resistance, dapagliflozin was not more effective at relieving congestion than metolazone. Patients assigned to dapagliflozin received a larger cumulative dose of furosemide but experienced less biochemical upset than those assigned to metolazone.
Study context
- Population
- Patients hospitalized for HF and resistant to IV furosemide
- Participants
- 61 patients
- Comparison
- Dapagliflozin vs metolazone
- Primary endpoint
- Diuretic effect, assessed by change in weight (kg)
- Follow-up
- 96 h
Primary result
As reported in the abstract
Secondary outcomes
Cumulative furosemide dose · 96 h
Mean
| Outcome | Dapagliflozin | Metolazone |
|---|---|---|
| Loop diuretic efficiency (weight change per 40 mg furosemide) | 0.15 (SD 0.12) | 0.25 (SD 0.19) |
Pulmonary congestion (lung ultrasound) and volume assessment score
- Changes similar between treatments
Safety
Serious adverse events
- Similar between treatments
Biochemistry (plasma sodium, potassium, urea, creatinine)
- Decreases in sodium and potassium and increases in urea and creatinine smaller with dapagliflozin than with metolazone
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Summarised from the published abstract; every number is checked against it